Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411407 | 1.00 | CA1 (0.39) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL3411401 | 1.00 | CA1 (0.39) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL29689842 | 0.81 | CTSK (0.41) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL9128673 | 0.79 | CA1 (0.39) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL22887890 | 0.79 | CA1 (0.39) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL1907844 | 0.77 | HSD17B10 (0.44) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL30388232 | 0.77 | HSD17B10 (0.44) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL1903239 | 0.76 | KLK5 (0.42) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL5653120 | 0.75 | CA1 (0.40) | CA1CA2EPHX1CTSKBTK | |
| SCHEMBL4524535 | 0.75 | CA1 (0.40) | CA1CA2EPHX1CTSKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1913900-B | Amino-substituted diaryl [ a, d ] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric diseases | ACADIA PHARM INC | 2010-11-24 | — | — | CN | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7622461-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| EP-2088147-A1 | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders | Arcadia Pharmaceuticals Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7550454-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7517871-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1696931-B1 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARM INC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008021463-A2 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1865962-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | Arcadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EK FREDRIK | 2007-08-23 | — | — | US | disclosed |
| WO-2006107948-A9 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARM INC (US) | 2007-02-22 | — | — | WO | disclosed |
| CN-1913900-A | Amino-substituted diaryl [ a, d ] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric diseases | ACADIA PHARM INC (US) | 2007-02-14 | — | — | CN | disclosed |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | ACADIA PHARMACEUTICALS INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-09-07 | — | — | US | disclosed |
| EP-1696931-A2 | AMINO SUBSTITUTED DIARYL [A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Acadia Pharmaceuticals Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005063254-A2 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CA1 1353/4885CA2 3927/4885EPHX1 1072/4885 |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CA1 1316/4885CA2 3899/4885EPHX1 1065/4885 |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | DRD3, DRD2, PNMT | CA1 4778/4885CA2 4725/4885EPHX1 4128/4885 |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRNA10 | CA1 1189/4885CA2 3370/4885EPHX1 1150/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | CA1 1189/4885CA2 3370/4885EPHX1 1150/4885 |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | OPRL1, CHRM4, CNR1 | CA1 1289/4885CA2 3486/4885EPHX1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.